Gregory P. Howard, Ph.D., is a technical specialist in Sterne Kessler’s Biotechnology & Chemical Group, where he assists with the preparation and prosecution of U.S. and foreign patent applications. His technical areas of expertise include immunology, vaccinology, materials science, polymer chemistry, molecular biology, non-viral and viral gene therapy, small molecule and protein therapeutics, biomedical engineering, and regenerative medicine.
Gregory earned his Ph.D. in Biomedical Engineering from Johns Hopkins University. There, he designed and developed nanoparticle and hydrogel vaccine platforms for infectious disease prevention and cancer treatment. His dissertation work focused on the synergistic combination of reprogrammed adjuvants, lymph-node targeting vaccines, and hydrogel vaccine depots to produce single administration vaccines for malaria and HIV with similar efficacy to traditional prime-boost vaccination regimens. Other work included the development of biomaterials for non-viral and viral gene therapy, small molecule delivery for the treatment of cancer, sustained release nanoparticle platforms for therapeutic delivery, and the application of hydrogels in regenerative medicine.
Before starting his graduate work, Gregory was a NIH Oxford Scholar at the National Institutes of Health and University of Oxford where he focused on developing antibody therapeutics for Ebolavirus as well as aided in assessing human serological samples for an Ebolavirus vaccine clinical trial. Gregory received his B.S. in Biomedical Engineering, summa cum laude, with minors in Chemistry and Mathematics from the University of Akron as an Honors Scholar. At his undergraduate institution, he worked on various research projects including the development of novel biomaterials for gene therapy with applications in cancer therapeutics and preeclampsia treatment.